NCT01698944View on ClinicalTrials.gov

Cardiovascular Effects on Growth Hormone Therapy in Adults With Growth Hormone Deficiency

PHASE4TerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

May 16, 2001

Primary Completion Date

November 18, 2002

Study Completion Date

November 18, 2002

Conditions
Growth Hormone DisorderAdult Growth Hormone Deficiency
Interventions
DRUG

somatropin

Initial dose 0.5 IU/day and escalated up to maximum dose the first 6 months. Maximum dose 3.0 IU/day for 18 months. Injected subcutaneously (s.c., under the skin) daily

Trial Locations (1)

GR-11527

Novo Nordisk Investigational Site, Athens

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY